A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice

Biochemical and Biophysical Research Communications

Volumn 398, Issue 3, 2010, Pages 506-512

  Qi, Zhi ^a   Pan, Chungen ^a   Lu, Hong ^a   Shui, Yuan ^a   Li, Lin ^a,b   Li, Xiaojuan ^b   Xu, Xueqing ^b   Liu, Shuwen ^b   Jiang, Shibo ^a,b  

^a NEW YORK BLOOD CENTER   (United States)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Fusion intermediate; Gp41; HIV 1; Neutralizing antibody response; Trimer; Vaccine

Indexed keywords

GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL FUSION; CLADISTICS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; VACCINATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; BIOMIMETIC MATERIALS; HIV ENVELOPE PROTEIN GP41; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 77955280069     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.06.109     Document Type: Article

References (35)

1. Fauci A.S., Johnston M.I., Dieffenbach C.W., et al. HIV vaccine research: the way forward. Science 2008, 321:530-532.
2. Steinbrook R. One step forward, two steps back - will there ever be an AIDS vaccine?. New Engl. J. Med. 2007, 357:2653-2655.
3. Flynn N.M., Forthal D.N., Harro C.D., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191:654-665.
4. Pantophlet R., Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 2006, 739-769.
5. Zwick M.B., Labrijn A.F., Wang M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001, 75:10892-10905.
6. Binley J.M., Wrin T., Korber B., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 2004, 78:13232-13252.
7. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 1995, 2:1075-1082.
8. Chan D.C., Fass D., Berger J.M., et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
9. Weissenhorn W., Dessen A., Harrison S.C., et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-428.
10. Chan D.C., Chutkowski C.T., Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. USA 1998, 95:15613-15617.
11. Dwyer J.J., Hasan A., Wilson K.L., et al. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry 2003, 42:4945-4953.
12. Jiang S., Lin K., Strick N., et al. HIV-1 inhibition by a peptide. Nature 1993, 365:113.
13. Wild C.T., Shugars D.C., Greenwell T.K., et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 1994, 91:9770-9774.
14. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell 1998, 93:681-684.
15. Pan C., Liu S., Jiang S. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics. J. Formos. Med. Assoc. 2010, 109:94-105.
16. Golding H., Zaitseva M., de Rosny E., et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J. Virol. 2002, 76:6780-6790.
17. Miller M.D., Geleziunas R., Bianchi E., et al. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. USA 2005, 102:14759-14764.
18. Louis J.M., Nesheiwat I., Chang L., et al. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J. Biol. Chem. 2003, 278:20278-20285.
19. Zhang M.Y., Wang Y., Mankowski M.K., et al. Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen. Vaccine 2008, 27:857-863.
20. Bianchi E., Joyce J.G., Miller M.D., et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc. Natl. Acad. Sci. USA 2010, 107:10655-10660.
21. Eckert D.M., Malashkevich V.N., Hong L.H., et al. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999, 99:103-115.
22. Bianchi E., Finotto M., Ingallinella P., et al. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc. Natl. Acad. Sci. USA 2005, 102:12903-12908.
23. Welch B.D., VanDemark A.P., Heroux A., et al. Potent D-peptide inhibitors of HIV-1 entry. Proc. Natl. Acad. Sci. USA 2007, 104:16828-16833.
24. Gao W., Rzewski A., Sun H., et al. UpGene: application of a web-based DNA codon optimization algorithm. Biotechnol. Progr. 2004, 20:443-448.
25. Sackett K., Wexler-Cohen Y., Shai Y. Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J. Biol. Chem. 2006, 281:21755-21762.
26. Jiang S., Lin K., Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J. Virol. 1998, 72:10213-10217.
27. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
28. Lu H., Zhao Q., Xu Z., et al. Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors. J. Virol. Meth. 2003, 107:155-161.
29. Jiang S., Lin K., Neurath A.R. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 1991, 174:1557-1563.
30. Jiang S., Lu H., Liu S., et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob. Agents Chemother. 2004, 48:4349-4359.
31. Liu S., Zhao Q., Jiang S. Determination of the HIV-1 gp41 postfusion conformation modeled by synthetic peptides: applicable for identification of the HIV-1 fusion inhibitors. Peptide 2003, 24:1303-1313.
32. Yang X., Lee J., Mahony E.M., et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 2002, 76:4634-4642.
33. Chen X., Lu L., Qi Z., et al. Novel recombinant engineered gp41 N-terminal heptad-repeat trimers: potential as anti-HIV-1 therapeutics or microbicides. J. Biol. Chem. 2010, (June 10). [Epub ahead of print].
34. Liu S., Jing W., Cheung B., et al. HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides. J. Biol. Chem. 2007, 282:9612-9620.
35. Dimitrov A.S., Louis J.M., Bewley C.A., et al. Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 2005, 44:12471-12479.